Compare Amphastar Pharmaceuticals Inc (AMPH) vs e l f Beauty Inc (ELF) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ELF trades at $76.75, up 1.31% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth and high gross margins, though valuation multiples appear elevated. Recent news highlights brand expansion and market share gains, with analyst sentiment mixed but leaning positive.

Outlook remains optimistic due to consistent earnings outperformance and strategic initiatives, but risks include high P/E ratio, competitive pressures, and sensitivity to tariffs. Upside potential exists if growth targets are met, yet investors should weigh valuation concerns against growth trajectory.